Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 172-181

  Da Costa, Andre Nogueira ^a   Plymoth, Amelie ^a,b   Santos Silva, Daniela ^a   Ortiz Cuaran, Sandra ^a   Camey, Suzy ^a,c   Guilloreau, Paule ^d   Sangrajrang, Suleeporn ^e   Khuhaprema, Thiravud ^e   Mendy, Maimuna ^a   Lesi, Olufunmilayo A ^f   Chang, Hee Kyung ^g   Oh, Jin Kyoung ^h   Lee, Duk Hee ⁱ   Shin, Hai Rim ^j   Kirk, Gregory D ^k   Merle, Philippe ^d,l   Beretta, Laura ^m   Hainaut, Pierre ^a,n,o,p  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d CROIX ROUSSE HOSPITAL   (France)

^e NATIONAL CANCER INSTITUTE   (Thailand)

^f LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^g Kosin Medical Centre   (South Korea)

^h National Cancer Center   (United States)

ⁱ Kyungpook National University   (South Korea)

^j WORLD HEALTH ORGANIZATION   (Switzerland)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^o UCB PHARMA   (Belgium)

^p UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

biomarkers; chronic liver disease; hepatocellular carcinoma; LTBP2; osteopontin

Indexed keywords

ALPHA FETOPROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 2; OSTEOPONTIN; TUMOR MARKER; UNCLASSIFIED DRUG; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LTBP2 PROTEIN, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CASE CONTROL STUDY; CHRONIC LIVER DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FRANCE; GAMBIA; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; THAILAND; VALIDATION STUDY; AREA UNDER THE CURVE; BLOOD; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; HEPATITIS B; LIVER NEOPLASMS; POVERTY; RECEIVER OPERATING CHARACTERISTIC; VIROLOGY;

AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; HEPATITIS B, CHRONIC; HUMANS; LATENT TGF-BETA BINDING PROTEINS; LIVER NEOPLASMS; OSTEOPONTIN; POVERTY; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84921772880     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28953     Document Type: Article

References (33)

1. Yang JD, Roberts LR,. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010; 24: 899-919.
2. Ferlay J, Shin HR, Bray F, et al., GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet], vol. 2011. Lyon, France: International Agency for Research on Cancer, 2010.
3. Yuen MF, Hou JL, Chutaputti A, et al., Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-53.
4. Srivatanakul P, Honjo S, Kittiwatanachot P, et al., Hepatitis viruses and risk of cholangiocarcinoma in Northeast Thailand. Asian Pac J Cancer Prev 2010; 11: 985-8.
5. Szymanska K, Lesi OA, Kirk GD, et al., Ser-249 TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer 2004; 110: 374-9.
6. Villar S, Le Roux-Goglin E, Gouas DA, et al., Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection. Environ Health Perspect 2011; 119: 1635-40.
7. Gomaa AI, Khan SA, Leen ELS, et al., Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 1301-14.
8. Farinati F, Marino D, De Giorgio M, et al., Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-32.
9. Trevisani F, D'Intino PE, Morselli-Labate AM, et al., Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-5.
10. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
11. Omata M, Lesmana LA, Tateishi R, et al., Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-74.
12. Villanueva A, Minguez B, Forner A, et al., Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-28.
13. Shang S, Plymoth A, Ge S, et al., Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55: 483-90.
14. Plymoth A, Boffetta P, Chuang S-C, et al., International efforts to combat liver cancer: IARC and ILCA initiatives. J Hepatol 2008; 49: 675.
15. Kirk GD, Lesi OA, Mendy M, et al., The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004; 39: 211-9.
16. Kuniholm MH, Lesi OA, Mendy M, et al., Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in The Gambia, West Africa. Environ Health Perspect 2008; 116: 1553-7.
17. Umoh NJ, Lesi OA, Mendy M, et al., Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int 2011; 31: 215-21.
18. Shin A, Cho ER, Kim J, et al., Factors associated with awareness of infection status among chronic hepatitis B and C carriers in Korea. Cancer Epidemiol Biomarkers Prev 2009; 18: 1894-8.
19. Shin HR, Won YJ, Jung KW, et al., Nationwide cancer incidence in Korea, 1999â2001; first result using the national cancer incidence database. Cancer Res Treat 2005; 37: 325-31.
20. Hyytiainen M, Keski-Oja J,. Latent TGF-beta binding protein LTBP-2 decreases fibroblast adhesion to fibronectin. J Cell Biol 2003; 163: 1363-74.
21. Hirani R, Hanssen E, Gibson MA,. LTBP-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar protein. Matrix Biol 2007; 26: 213-23.
22. Vehvilainen P, Hyytiainen M, Keski-Oja J,. Matrix association of Latent TGF-Beta Binding Protein-2 (LTBP-2) is dependent on Fibrillin-1. J Cell Physiol 2009; 221: 586-93.
23. Azmanov DN, Dimitrova S, Florez L, et al., LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population. Eur J Hum Genet 2011; 19: 326-33.
24. Chan SHK, Ko JMY, Chan KW, et al., The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome. Int J Cancer 2011; 129: 565-73.
25. Turtoi A, Musmeci D, Wang Y, et al., Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res 2011; 10: 4302-13.
26. Torres S, Bartolome RA, Mendes M, et al., Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res 2013; 19: 6006-19.
27. Ramaiah SK, Rittling S,. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008; 103: 4-13.
28. Kim J, Ki SS, Lee SD, et al., Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006; 101: 2051-9.
29. Zhang CH, Xu GL, Jia WD, et al., Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012; 130: 2685-92.
30. Zhao J, Dong L, Liu B, et al., Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008; 135: 956-68.
31. Zhao L, Li T, Wang Y, et al., Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008; 62: 1056-62.
32. Lai KKY, Shang S, Lohia N, et al., Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and PTEN null mouse models. PLoS Genet 2011; 7: e1002147.
33. Hernandez-Gea V, Friedman SL,. Pathogenesis of liver fibrosis. In: Abbas, A. K. Galli S. J. Howley P. M. eds. Annual review of pathology: mechanisms of disease, vol. 6, Annual Reviews. 2011. 425-56, ISBN: 1553-4006 978-0-8243-4306-4.